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ABSTRACT
The first generation of CB1 positive allosteric modulators (PAMs; e.g., ZCZ011) featured a 3-nitroalkyl-
2-phenyl-indole structure. Although a small number of drugs include the nitro group, it is generally 
not regarded as being “drug-like”, and this is particularly true for aliphatic nitro groups.  There are 
very few case studies where an appropriate bioisostere replaced a nitro group that had a direct role 
in binding. This may be indicative of the difficulty of replicating its binding interactions. Herein we 
report the design and synthesis of ligands targeting the allosteric binding site on the CB1 cannabinoid 
receptor, in which a CF3 group successfully replaced the aliphatic NO2. In general, the CF3-bearing 
compounds were more potent than their NO2 equivalents and also showed improved in vitro 
metabolic stability. The CF3-analogue (1) with the best balance of properties was selected for further 
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pharmacological evaluation. Pilot in vivo studies showed that (±)-1 has similar activity to (±)-ZCZ011, 
with both showing promising efficacy in a mouse model of neuropathic pain.
INTRODUCTION
The endocannabinoid system plays a major role in modulating neurotransmitter release in the central 
nervous system and thus its modulation elicits a broad range of physiological effects. Compounds 
activating cannabinoid receptors represent a promising therapeutic opportunity for the treatment of 
many disorders, including depression, anxiety and pain. However, global activation of the cannabinoid 
CB1 receptor by direct agonism leads to psychoactive side effects, physical dependence and abuse 
liability. There is both an opportunity and a need to provide safer and more effective ways of 
harnessing the therapeutic benefits of CB1 receptor activation. Recent reviews have highlighted the 
therapeutic potential of targeting the allosteric binding site on the CB1 receptor using positive 
allosteric modulators (PAMs),1,2 which have the advantage of enhancing the actions of 
endocannabinoids directly at the orthosteric receptors expressed within spinal and brain pain 
processing centres. Thus, PAMs are predicted to be free of the psychoactive side-effects associated 
with direct CB1 agonists that globally activate these receptors. The impressive efficacy of small 
molecule tool CB1 PAMs in models of neuropathic pain and post-traumatic stress disorder, without 
any evidence of addiction or psychotropic side-effects, support this hypothesis.
N
H
NO2
N
H
NO2S
AZ-4 / GAT211 ZCZ-011 (5)
Figure 1
The activity of the first CB1 PAM - AZ-4,3 also known as F-0874 and now commonly referred to as GAT-
2115 (Figure 1), was reported in a conference poster by researchers at AstraZeneca Montreal,3 having 
been first synthesised by Noland and Lange in 1959.6  The structure has since been modified to 
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improve potency (ZCZ011,7 5 in Table 1) and the enantiomers of AZ-4 separated (GAT228/229)5, but 
no substantial development or comprehensive structure activity relationships have been reported. 
The primary problematic issue with these compounds is the presence of an aliphatic nitro group. 
Despite its presence in a small number of major drugs, including nifedipine, chloramphenicol, 
ranitidine and metronidazole, most academic and industrial medicinal chemists do not regard a nitro 
group as being “drug-like”. However, surprisingly little published evidence exists to support this 
blanket exclusion of the nitro-group from drug-like space.  Justification for this exclusion may be based 
upon accepted wisdom, or derived from personal experience (see e.g. Muegge and co-workers;8 Beck 
and co-workers;9 and discussions on internet forums, including the well-regarded “In the 
Pipeline”10,11); or based on a well-established (if only potential) toxic liability associated solely with the 
aromatic nitro and its propensity for formation of an aryl nitrenium ion, which can bind to DNA.12  In 
additional examples of this general dismissal of the nitro group from drug-like space, the nitro was 
one of the groups eliminated prior to the studies leading to Baell’s identification of the range of pan-
assay interference compounds13; likewise, any structures containing a nitro are explicitly excluded by 
Rankovic and Morphy14 as being acceptable for use in fragment-based lead discovery. 
While little information exists on the toxicological issues associated with aliphatic nitro groups, the 
widely-held opinions described above usually require its removal or replacement early in the 
development of a bioactive compound. However, there are only a few case studies in which a nitro 
group has been successfully replaced by an appropriate bioisostere,9 which may be indicative of the 
difficulty of replicating its binding interactions. Nitro groups may act as hydrogen bond acceptors and 
may also stack with other groups, including ketones and alcohols.15  Additionally, Alston and co-
workers16 reported that the nitroalkyl group can serve as a one- and two-electron reductant, oxidant, 
ambident nucleophile, electrophile, ligand, and leaving group in reactions with enzymes and other 
biomolecules and suggested that “the richness of its reactivity may have hindered the application of 
the nitroalkyl group in medicinal chemistry.” Much more commonly, nitro groups are initially present 
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in bioactive compounds as aromatic substituents, where their electron-withdrawing properties may 
polarise the ring, giving optimal interaction with electron-rich moieties within the biological target. In 
such cases, simple replacement with other strongly-electron-withdrawing substituents, e.g. halogens 
or haloalkyl groups, may be possible.  
Because of this strong electron-withdrawing nature, the presence of a nitro group also facilitates many 
chemical reactions; thus, it is often found in screening collections (including the collection from which 
AZ-4 was originally identified). The reaction of an indole with nitrostyrene has been widely reported 
in the literature and there are a considerable range of methods available for this simple 1,4-conjugate 
addition reaction.17–24  There is literature precedent for the nitro group to be replaced with a carboxylic 
acid in this series of compounds, which is achieved by initial reaction of an indole with the highly-
electron deficient diethylbenzylidene malonate.21,22 The limited similarity of nitro group binding to 
carboxylic acid binding, in spite of the near perfect isosterism, has been discussed by Kelly and Kim.25 
A small range of derivatives can be accessed from the carboxylic acid (e.g. CH2OH, CO2H, CO2Et, 
CONHNH2, CONH2 and CONHMe, Figure 2 - see Supporting Information); however, these were inactive 
as CB1 PAMs. 
N
H
NR1R2
N
H
COR1
Figure 2.
Likewise, simple derivatives based on reduction of the nitro to an amine (Figure 2), with or without 
subsequent substitution, gave inactive compounds (see Supporting Information). 
Modelling studies on GAT22826 indicate that the nitro group may form polar interactions with a serine, 
a methionine and a cysteine residue in the absence of the orthosteric agonist (CP55,940).  However, 
this case appears to apply to an orthosteric agonist. Although not stated as a conclusion by the 
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authors, the modelling suggests that, in the presence of an agonist, GAT228 moves deeper into the 
receptor; accordingly, the nitro group may be too far from these binding groups to retain a strong 
interaction. Thus, it remains uncertain that specific binding interactions provided by the nitro group 
are required for its activity as a PAM. However, the lack of activity shown by any of the compounds in 
Figure 2 suggests that such interactions will be necessary for PAM activity.
Herein we report that the CF3 offers a viable bioisosteric replacement for an aliphatic nitro group, 
demonstrating the removal of the non-drug-like nitro group from the most-commonly-studied and 
utilised CB1 PAMs, to achieve compounds with improved potency and metabolic stability.
RESULTS AND DISCUSSION
Chemistry. 
A library of indole derivatives 1-57 (Table 1) was synthesised using a variety of methods. Nitro-indole 
derivatives 2-25 were obtained by InBr3-catalyzed Michael addition of 2-(2-nitrovinyl)-aryl/heteroaryl 
derivatives to the corresponding indoles, upon microwave heating (see Supporting Information 
Scheme SI-1 for details). Dicyano derivatives 29 and 32-34 having R2 = Ph and R4 = CH(CN)2 were 
obtained by addition of lithium indolyl-cuprate(I) to benzylidene-malononitriles (Supporting 
Information, Scheme SI-4). Compounds having R2 = Ph and R4 = CH2CN were obtained either via Fischer 
indole syntheses (28, 30), or via InBr3-promoted addition of phenyl-oxirane to an indole, followed by 
one-carbon homologation (31). A similar strategy, followed by one-carbon homologation using TMS-
CF3 and Barton-McCombie dehydroxylation was used to access the CF3-indoles 37 and 39 (Supporting 
Information, Scheme SI-5). The cyclopropyl CF3-indole 40 was also prepared using a multi-step process 
involving TMS-CF3 homologation and Barton-McCombie dehydroxylation (Supporting Information, 
Scheme SI-7). However, the most versatile method for efficiently preparing a wide range of CF3-indoles 
is shown in Scheme 1. The starting indole was iodinated at the 3-position with NIS to be then subjected 
to Sonogashira coupling to give 79. Terminal alkyne trifluoromethylation with in-situ generated "Cu-
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CF3" under aerobic conditions gave CF3-alkynes 80,27 which were transformed into iodo-alkenes 81 
with lithium iodide under mild acidic aonditions,28 which were then submitted to Stille coupling with 
the corresponding aryl stannanes leading to N-MOM-protected indoles 82. The latter were first de-
protected with HCl and then reduced with Et3SiH in the presence of TFA to afford the target CF3-indoles 
1, 41-50 and 57.
N
MOM
R3
N
MOM
R3
N
MOM
R3
CF3
N
MOM
R3
I
CF3
e)
N
MOM
R3
R2
CF3
N
H
R3
R2 CF3
79 80
81821, 41-50, 57
R1
R1 R1
R1R
1R1
a)-c) d)
f)g)
Scheme 1. Synthesis of CF3-PAMs via Stille coupling/ionic hydride reduction strategy.
Reagents and conditions:  a) NIS, 0 °C, CH2Cl2; b) TMSCCH, PdCl2(PPh3)2, CuI, ET3N, 23 °C, DMF; c) TBAF, 0 °C, THF; 
d) TMSCF3, CuI, TMEDA, K2CO3, air, 23 °C, DMF; e) LiI, HOAc, CH2Cl2, 0 – 23 °C; f) R2SnBu3, PdCl2(MeCN)2, P(o-
Tol)3, CuI, 55 °C, DMF; g) 6 M HCl, 60 °C, THF then Et3SiH, TFA, 0 – 23 °C, CH2Cl2.
Further late-stage functional groups manipulations, shown in Scheme 2, expanded the library of CF3-
indole derivatives to include compounds 52-56 and 83-89.
N
H
Ph
N
H
CF3
S
O O
S
N
H
Ph
O
O
S
50
N
Ph
O
O
CF3
S
SEM
N
Ph
N
O
CF3
S
O
SEM
N
Ph
O
CF3
S
SEM
N
Ph
N
CF3
S
SEM
N
H
Ph
O
CF3
S
HO
N
Ph
N
H
CF3
S
SEM
O
N
Ph
H2N
CF3
S
SEM
N
H
Ph
N
H
CF3
S
53
O
N
H
Ph
H2N
CF3
S
N
Ph
N
H
CF3
S
SEM
S
O O
54 55 56
b)
i)
c) d) e) f) g) h)
CF3
N
H
Ph
S
52
CF3
HO
i) i)
a)
i)
83 84 85 86 87 88 89
Scheme 2. Late-stage functional group interconversions strategy.
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Reagents and conditions: a) Super-Hydride®, THF; b) SEMCl; c) HNMe(OMe)-HCl, iPrMgCl, THF,  0 oC; d) MeLi, 
THF, -78 oC; e) NH2OH-HCl; f) cyanuric chloride, DMF, 23 oC; g) N2H4 hydrate, EtOH, 100 oC; h) MeSO2Cl, Et3N, 23 
oC; i) HFaq-TFA.
All the compounds above were obtained in racemic form, but pure enantiomers could be obtained for 
a number of derivatives, such as 1, 8, 26 and 50, using preparative HPLC separation on chiral column 
(see Supporting Information for details). Compound (+)-1 was crystallized from EtOAc/Hexane 
solution and its structure was determined by X-ray crystallography,29 which showed that the 
stereogenic centres C9 and C31 had (S)-configurations (Figure 3). Note, as a consequence of the 
change of priority of the substituents, (R)-()-1 and (S)-()GAT229 have different descriptors but share 
the same stereocentre’s topicity.
NC NH
CF3S
(S)-(+)-1
(ABD1235)
(S)-(+)-1
(ABD1235)
Figure 3. X-ray crystal structure of (S)-(+)-1.
In vitro pharmacology. Modification of the ZCZ011 structure indicated that either a 6-Me (5), 6-Cl (6), 
6-CF3 (7) or 6-CN (8) substitution led to moderately potent and efficacious CB1 PAMs, as determined 
by enhancement of β-arrestin recruitment, induced by the CB1 agonist CP55,940 at its EC20 in the 
PathHunter® β-Arrestin assay (Eurofins DiscoverX), by a variation of the methods described 
previously.7 The results are shown in Table 1. Substitutions on the 5-position of the indole gave 
compounds with poor potency [5-Me (2), 5-CN (3), 5-NO2 (4)]. However, results from the same assay 
demonstrated that, alongside their PAM activity, most of these compounds were also allosteric 
agonists, giving receptor activation in the absence of the orthosteric ligand. This compares with 
previous reports5 that the enantiomers of AZ-4 (GAT228 and 229) show considerable differences in 
their properties, with the (+) enantiomer being an allosteric agonist and the () being a pure PAM. 
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Separation of the enantiomers of (±)-8 (6-CN) confirmed that ()-8 was the more potent PAM but, 
contrary to GAT228/229,5 did not indicate that the (+)-8 was an agonist: both ()- and (+)-8 showed 
enhancement of CP55,940-induced β-arrestin recruitment (Emax = 117% and 51% for the () and (+) 
respectively, p<0.005 between enantiomers) with EC50 values that were not significantly different (664 
and 863 nM, for the () and (+) respectively). However, both showed very low agonism (activation in 
the absence of CP55,940) (Emax = 21 and 6% for the () and (+) respectively) with very poor potency 
(EC50 >10 µM) making them both effectively pure PAMs (Table 1). Replacement of the 2-phenyl group 
(R3) with different aryl or cycloalkyl groups as in 9-25 was not tolerated. Other researchers30 have 
noted that, in the absence of any (R1) substitutions on the indole, 4-fluoro, 4-chloro or 3-chloro-4-
fluoro substitution on the 2-phenyl (R2) appeared to be beneficial for potency in a cAMP assay; 
however, no examples featuring both an R1 and R2 substitution were shown. 
In addition to the potential toxicological concerns, the methylene group adjacent to the nitro group 
was expected to be acidic and potentially a metabolic liability, contributing to the short half-life. 
ZCZ011 (5) was shown to be highly unstable in the rat and mouse liver microsomal assays (t½ < 10 min), 
with moderate stability in human liver microsomes (t½ = 41 min) (Cyprotex Ltd). No significant increase 
in stability was seen with the 6-Cl (6) and 6-CF3 (7) derivatives or with the placement of an electron-
withdrawing 4-Cl on the 2-phenyl group (16) (see Table 1). We therefore concluded that further 
development of the nitro-bearing compounds was unlikely to lead to drug-like compounds (suitable 
either for preclinical development or as tool compounds for in vivo target validation studies), and set 
about developing the synthetic methods required to permit replacement of the nitro group with a 
range of bioisosteres. 
Modelling software (FieldStere and FieldAlign, products available from Cresset Biomolecular at the 
time) was used to suggest moieties that might mimic the electronic properties of the nitro group, with 
the primary feature modelled being that of a hydrogen bond acceptor. Many structures were 
identified, but synthetic methods were generally lacking. Various 5-membered heterocycles were 
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investigated (Fig. 4); however, none of these were active and the syntheses were not straightforward. 
Thus, this line of investigation was terminated because of unproductivity.
N
H
N
NN
N
N
H
N
N
NN
N
H
N N
N
N
H
N N
Figure 4. Inactive heterocyclic analogues of ZCZ011 investigated in this work (see Supporting 
Information: Het-1 – Het-4). 
The cyano group is sometimes proposed as being a bioisostere for a non-aromatic nitro group;31 
although perhaps the most widely known example of this is in fact the use of nitro as a bioisostere of 
a cyano group, as seen in the development of ranitidine from cimetidine.32 This bioisosterism was 
affirmed by the (albeit modest) potency of compounds 30 and 32, which featured replacement of the 
CH2NO2 with either a CH2CN or a CH(CN)2 moiety. Compound 31 showed trends for somewhat reduced 
potency and efficacy as compared to its nearest nitro analogue (not significant), and showed similarly-
poor metabolic stability in rat liver microsomes, possibly again related to the acidity of the proton 
adjacent to the CN group(s). 
Studies aimed at replacement of the stereogenic carbon atom with an amine led to the preparation 
of a range of compounds bearing a -COCF3 substituent, some of which (such as compounds 58 and 59, 
Fig. 5) showed a modest degree of enhancement (~50% at 1 µM).
N
H
N CF3
O
N
H
N CF3
O
58 59
Figure 5. Trifluoroacetamide derivatives tested in this work.
It was assumed that these compounds would be highly susceptible to hydrolysis and they were not 
regarded as development candidates or even appropriate for use as tool compounds. However, these 
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results suggested that the –CF3 group might be a suitable bioisostere. Consequently, we set about 
developing synthetic methodologies to allow access to target compounds.
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N
H
R3
R2 R4
R1
EC50 Emax fT1/2 (min)
Comp R1 R2 R3 R4
aPAM Activity: 
>50 %
enhancement
* at 1000 nM 
** at 500 nM 
*** at 200 nM
bPAM cAgo dPAM dAgo HLM RLM MLM
2 5-Me 2-Thienyl Ph CH2NO2 * - - - - - - -
3 5-CN 2-Thienyl Ph CH2NO2 NA - - - - 49.4 8.2 -
4 5-NO2 2-Thienyl Ph CH2NO2 NA - - - - - - -
5 6-Me 2-Thienyl Ph CH2NO2 ** 283±140 777±363 106±18 55±24 41.2±3.1 6.4±1.2 10.4±2.1
6 6-Cl 2-Thienyl Ph CH2NO2 ** 462±363 1530±1128 154±10 82±48 32.7 13.8 -
7 6-CF3 2-Thienyl Ph CH2NO2 ** 284±211 974±780 163±17 106±47 30.7 15.6 -
(±)-8 6-CN 2-Thienyl Ph CH2NO2 * - - - - - - -
(+)-8 6-CN 2-Thienyl Ph (+)CH2NO2 * 863±211 >10000 51±18## 9±4# - - -
(-)-8 6-CN 2-Thienyl Ph (-)CH2NO2 * 664±215 >10000 117±19## 21±6# - - -
9 6-Cl 2-Thienyl 4-OMe-C6H4- CH2NO2 NA - - - - - - -
10 6-Cl 2-Thienyl 4-NMe2-C6H4- CH2NO2 NA - - - - - - -
11 6-Cl 2-Thienyl 4-CN-C6H4- CH2NO2 NA - - - - - - -
12 6-Cl 2-Thienyl 4-CO2Me-C6H4- CH2NO2 NA - - - - - - -
13 6-Cl 2-Thienyl 4-SO2Me-C6H4- CH2NO2 NA - - - - - - -
14 6-Cl 2-Thienyl 4-COOH-C6H4- CH2NO2 NA - - - - - - -
15 6-Cl 2-Thienyl 4-Ac-C6H4- CH2NO2 NA - - - - - - -
16 6-Me 2-Thienyl 4-Cl-C6H4- CH2NO2 NA - - - - 24.2 9.8 -
17 6-Cl 2-Thienyl 4-Cl-C6H4- CH2NO2 NA - - - - - - -
18 6-Cl 2-Thienyl 4-F-C6H4- CH2NO2 NA - - - - -
19 6-Me 2-Thienyl 4-F-C6H4- CH2NO2 NA - - - - - - -
20 6-Cl 2-Thienyl 3-OMe-C6H4- CH2NO2 NA - - - - -
21 6-Cl 2-Thienyl 3-CN-C6H4- CH2NO2 NA - - - - -
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22 6-Me 2-Thienyl Cyclopropyl CH2NO2 * - - - - -
23 6-Me 2-Thienyl Cyclopentyl CH2NO2 * - - -
24 6-Me 2-Thienyl Cyclohexyl CH2NO2 NA - - - - - - -
25 5-CN 2-Thienyl Cyclohexyl CH2NO2 NA - - - - 21.4 3.8 -
(±)-26 - Phenyl Ph CH2CO2H NA - - - - 62.7 - -
(+)-26 Phenyl Ph CH2CO2H NA - - - - - - -
(-)-26 Phenyl Ph CH2CO2H NA - - - - - - -
27 - Phenyl Ph CH2OH NA - - - - - - -
28 - Phenyl Ph CH2CN NA - - - - 42.7 14.5 -
29 - Phenyl Ph CH(CN)2 NA - - - - 26.2 14.8 -
30 6-Me Phenyl Ph CH2CN * - - - - 45.7 18.7 -
31 6-Cl Phenyl Ph CH2CN * 1113±401 2354±601 100±36 24±7 43.2 22.5 -
32 6-Me Phenyl Ph CH(CN)2 * - - - - 39.3 12.4 -
33 6-Me 2-Thienyl Ph CH(CN)2 * - - - - 31.2 4.9 -
34 6-Cl 2-Thienyl Ph CH(CN)2 NA - - - - 29.6 13.5 -
35 - Phenyl Ph COCF3 NA - - - - 51.1 41.4 -
36 - Phenyl Ph CHOHCF3 NA - - - - 39.4 18.2 -
37 - Phenyl Ph CH2CF3 * - - - - 85.2 40.7 -
38 6-Me Phenyl Ph COCF3 ** - - - - 267 24.8 -
39 6-Me Phenyl Ph CH2CF3 ** - - - - 87.2 28.2 -
40 6-Me Cycloprop-yl methyl Ph CH2CF3 * - - - - 74.4 19.8 -
41 6-Me 2-Thienyl Ph CH2CF3 ** - - - - 108 17.5 -
42 6-Me 2-Furyl Ph CH2CF3 * - - - - 59.1 10.3 -
43 6-Cl 2-Furyl Ph CH2CF3 ** - - - - 63.9 46.3 -
44 6-Cl 2-Thienyl Ph CH2CF3 *** - - - - 157 54.3 -
45 6-Cl Phenyl Ph CH2CF3 - - - - 98.6 78.0 -
46 6-CF3 Phenyl Ph CH2CF3 *** - - - - - - -
47 6-CF3 2-Thienyl Ph CH2CF3 ** 322±252 801±554 203±54 95±15 49.7 36.7 -
48 5-Me Phenyl Ph CH2CF3 NA - - - - - - -
49 5-Me 2-Thienyl Ph CH2CF3 NA - - - - - - -
(±)-50 6-CO2Me 2-Thienyl Ph CH2CF3 *** - - - - - - -
(+)-50 6-CO2Me 2-Thienyl Ph CH2CF3 *** 160±147‡‡ 682±211‡ 88±28## 26±5## - - -
(-)-50 6-CO2Me 2-Thienyl Ph CH2CF3 *** 113±62‡ 416±167‡ 156±41## 51±11## - - -
51 6-CO2H 2-Thienyl Ph CH2CF3 NA - - - - - - -
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52 6-CH2OH 2-Thienyl Ph CH2CF3 NA - - - - - - -
53 6-NHAc 2-Thienyl Ph CH2CF3 NA - - - - - - -
(±)-1 6-CN 2-Thienyl Ph CH2CF3 *** 177±66 647±270 100±25 30±14 - - -
(S)-(+)-1 6-CN 2-Thienyl Ph CH2CF3 ** 342±142‡ 1206±345‡ 79±32# 17±4 - - -
(R)-(-)-1 6-CN 2-Thienyl Ph CH2CF3 ** 363±169‡‡ 828±310‡‡ 125±29# 25±6 72.3±30.5 34.9±7.4 26.5±1.5
54 6-Ac 2-Thienyl Ph CH2CF3 *** 158±60 741±362 121±23 39±9 51.2 12.2 -
55 6-NH2 2-Thienyl Ph CH2CF3 NA - - - - - - -
56 6-NHSO2Me 2-Thienyl Ph CH2CF3 NA - - - - - - -
57 6-CF3 2-Thienyl Cyclopentyl CH2CF3 ** 301±66 755±237 162±47 68±14 47.1 44.4 -
Table 1: Enhancement of β-arrestin recruitment induced by the CB1 agonist CP55,940 and metabolic stability data from human, rat and mouse liver 
microsomal stability studies (HLM, RLM and MLM).  aPilot data were generated as described previously7 and represents data from a single experiment. 
bSelected compounds were evaluated by Eurofins DiscoverX in three independent experiments, using the PathHunter® β-Arrestin assay. Positive allosteric 
modulation was assessed using EC20 CP55,940. The EC50 value represents the compound concentration at which 50% of the maximal achievable EC20 CP55,940-
induced β-arrestin recruitment is seen (± standard deviation) for each specific compound. cAgonism was evaluated in the same assay and EC50 and Emax values 
were generated as described for positive allosteric modulation, using compound alone in the absence of agonist.  dThe Emax for each compound is the maximum 
EC20 CP55,940-induced β-arrestin recruitment relative to the maximum achievable with CP55,940. eHuman, rat and mouse liver microsomal stability studies 
were conducted Cyprotex Ltd. Half-life values represent data from a single experiment (5 timepoints), except where ± stdev is given (three independent 
experiments).  ## P<0.005; #  P<0.05, between enantiomers (Student’s t-test). ‡‡ P< 0.005 ‡ P<0.05, between IC50 values as PAM and agonist (two-tailed t-
test). NA = not active (defined as <50% enhancement in CP55,940-induced β-arrestin recruitment at 1 µM).
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The unsubstituted derivatives (35, 36 and 37) featuring the CH2CF3, COCF3 and CH(OH)CF3 showed a 
small degree of enhancement (30 – 50%) at 1 µM (see Table 1). Incorporation of the 6-methyl group 
from ZCZ011 (compounds 38 and 39) gave a further increase in potency and efficacy (50 – 100% 
enhancement at 300 nM). Compounds showed good stability in human liver microsomes, and 
potential improvement in rat liver microsomes (RLM) compared to their nitro analogues (see Table 1). 
We prepared a range of CF3-derivatives (40-57) with the aim of SAR elucidation and further 
improvements in potency and metabolic stability. Several compounds showed excellent potency and 
efficacy, with enhancement of over 100% at <200 nM and HLM/RLM T1/2 >50 min; however, results 
from these compounds tended to be variable, due to solubility issues not seen with the nitro 
derivatives. In order to address these solubility issues, we prepared analogues with a range of polar 
substituents on the indole. In parallel, we used the nitro series of compounds as a model system for 
rapid preparation of the analogues bearing substituents on the 2-phenyl group. Unfortunately, these 
studies showed an unforgiving SAR (see Supporting Information for observations on the SAR) in that 
none of the substitutions on the 2-phenyl were tolerated and none of 6-CO2H (51), 6-CH2OH (52), 6-
NHAc (53), 6-NH2 (55) or 6-NHSO2Me (56) gave active compounds. The 6-Ac derivative (54) was potent 
and efficacious but showed poor stability in the RLM assay (T1/2 = 12 min). Results are shown in Table 
1.
Aside from those compounds with solubility issues, the most potent derivative was the 6-CO2Me (50) 
for which the enantiomers were separated. As expected from GAT228/2295 and our own observations 
from nitro compound 8, as shown in Table 1, the () enantiomer was significantly more efficacious 
(p<0.005) than the (+) enantiomer both as a PAM (Emax = 156±41 vs 88±28%, for the () and (+) 
respectively; and as an agonist (Emax = 51±11 vs 26±5%, for the () and (+) respectively).  Both the () 
and (+) enantiomers were more potent (p<0.05) as PAMs than as agonists (EC50 = 113±62 / 160±147 
nM for the () and (+) respectively as PAMs vs EC50 = 416±167 / 682±211 nM for the () and (+) 
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respectively as agonists. However, as an ester, compound 50 was assumed to be unsuitable for further 
evaluation, due to metabolic instability and, unfortunately, the likely metabolite (the 6-CO2H analogue 
51) was inactive.
The compound with the best balance of properties was the 6-CN analogue (1). As with the 6-CO2Me 
analogue 50, both the () and (+) enantiomers were significantly (p<0.05) more efficacious as PAMs 
(Emax = 125±29 / 79±32% for the () and (+) respectively) than as agonists (Emax = 25±6 / 17±4% for the 
() and (+) respectively); with the () significantly more efficacious than the (+) enantiomer (p<0.05) 
as a PAM. Likewise, both the () and (+) enantiomers were more potent (p<0.05) as PAMs than 
agonists (EC50 = 363±169 / 342±142 nM as PAMs, for the () and (+) respectively; and IC50 = 828±310 
/ 1206±345 nM as agonists, for the () and (+) respectively). The 6-CN derivative ()-1 was considerably 
more stable than ZCZ011, with HLM/RLM/MLM T1/2 of 72.3±30.5 (N.S. in comparison with ZCZ011) / 
34.9±7.4 (p<0.005 to ZCZ011) / 26.5±1.5 min (p<0.005 to ZCZ011) respectively, compared to 41.2±3.1 
/ 6.4±1.2 / 10.4±2.1 min respectively for ZCZ011. Results are shown in Table 1.
Thus, compound ()-1 was selected for further pharmacological evaluation. The enantiomers of CF3-
derivative 1 and the enantiomers of its nitro analogue 8 were compared to ZCZ011 in several assays, 
to assess further the bioisosterism of the -CF3 and -NO2 groups.  
A similar pattern for compound potency, but not efficacy, was seen in the DiscoverX Hithunter® cAMP 
assay (Eurofins DiscoverX): -CF3-bearing compounds 1 showed a trend for greater potency, than their 
-NO2 equivalents 8, and the () enantiomers also showed a trend for greater potency than their (+) 
analogues. The results are shown in Table 2. However, contrary to the situation seen with β-arrestin 
recruitment, the compounds possessed similar efficacy, with all compounds acting as both PAMs and 
full agonists, completely inhibiting forskolin-stimulated cAMP production. The significance of this 
apparent difference between the effects on β-arrestin and cAMP is unclear. However, it must be noted 
that, as neither ZCZ011 or (±)-1 showed any activity in the tetrad or psychoactive effects (see 
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Supporting Information), agonism, with regard to cAMP signalling, does not appear to translate to 
agonism at CB1 in vivo. 
cAMP EC50 (nM) cAMP Emax (%)
PAM Agonist PAM Agonist
ZCZ011 18 ± 1 32 ± 10 98 ± 0 94 ± 4
(+)-8 181 ± 95 251 ± 75 102 ± 5 96 ± 2
()-8 36 ± 10 46 ± 7 99 ± 2 97 ± 2
(S)-(+)-1 40 ± 17 76 ± 8 96 ± 3 89 ± 6
(R)-()-1 17 ± 5 29 ± 6 90 ± 1 84 ± 8
Table 2. Effects of compounds on cAMP generation, either alone (Agonist) or induced by EC20 CP55,940 
(PAM) in the presence of EC80 forskolin in the DiscoverX Hithunter® cAMP assay, using a variation of 
the methodology described previously.7 Data is the result of three independent experiments. 
Binding studies were also conducted (Eurofins Cerep) using a variant of the methodology described 
previously7 and demonstrated that, like ZCZ011, 1 µM (+)-1 and ()-1, showed a significant 
enhancement in binding of the CB1 agonist, [3H]CP55940. At this concentration, no enhancement was 
noted with either (+)-8 and ()-8. The results are shown in Table 3.
% Enhancement of 
[3H]CP55,940 binding
ZCZ011 127.1 ± 13.3
(+)-8 99.0 ± 10.1
()-8 108.4 ± 8.3
(S)-(+)-1 144.4 ± 3.5
(R)-()-1 131.4 ± 4.3
Table 3. Effect of 1 µM ZCZ011, (+)-8, ()-8, (+)-(S)-1 or (R)-()-1 on [3H]CP55,940 binding, using a 
variation of the methodology described previously.7 Data is the result of three independent 
experiments.
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In vivo efficacy. Using the methodology previously described for the racemic ZCZ011,7 (±)-1 was 
evaluated in several CB1 receptor-sensitive in vivo models and was shown to possess a similar activity 
profile as ZCZ011.
(±)-1 (40 mg/kg) did not elicit pharmacological effects in the tetrad assay when administered alone. 
(±)-1 did not affect either the distance travelled or immobility time during assessment of locomotor 
behavior, did not produce antinociception in the tail withdrawal test, did not produce hypothermia or 
cause immobility in the catalepsy bar test (see Supporting Information).  Thus, even at a high dose, 
(±)-1 did not elicit in vivo effects indicative of CB1 receptor orthosteric agonism.  In contrast, (±)-1 (40 
mg/kg) augmented a subset of pharmacological effects of the CB1 receptor orthosteric agonist 
CP55,940. Importantly, (±)-1 produced significant leftward shifts in the dose-response relationships of 
CP55,940 in producing antinociception in the tail withdrawal test (see Supporting Information) and 
thus was further evaluated for its potential in the mouse chronic constrictive injury of the sciatic nerve 
(CCI) model of neuropathic pain. 
As shown in Figure 6, mice displayed profound mechanical allodynia seven days post CCI surgery in 
both the ipsilateral (Panel A) and contralateral (Panel B) paws. At 40 mg/kg (the same dose at which 
ZCZ011 produces anti-allodynic effects7) (±)-1 significantly reversed CCI-induced mechanical allodynia 
in a time-dependent manner in the ipsilateral [Ftime(6, 168)=6.411; Fdrug(3, 28)= 101.5; P<0.0001; 
Finteraction(18, 168) = 7.394; P<0.0001, Figure 6A] and contralateral [Ftime(6, 168)=14.81; Fdrug(3, 28) = 
182.2; Finteraction(18, 168) = 4.901; P<0.0001, Figure 6B] paws. In particular, (±)-1 produced a significant 
anti-allodynic effect at 0.5 h post-administration and achieved maximal effectiveness by 1 h. 
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Figure 6. Acute administration of 40 mg/kg (±)-1 time-dependently reverses CCI-induced mechanical 
sensitivity in ipsilateral and contralateral paw.  Data are expressed as mean ± SEM (n = 8/group).  
****p<0.0001, *p<0.05 vs sham+vehicle; ###p<0.001 ##p<0.01, #p<0.05 vs CCI+vehicle. pre-sx (pre-
surgery); post-sx (post-surgery).
CONCLUSION
In conclusion, we have demonstrated that a -CF3 serves as a viable bioisosteric replacement for an 
aliphatic nitro group. Thus, we have shown that it is possible to remove the “non-drug-like” nitro group 
from the most-commonly-studied CB1 PAMs to give compounds with improved potency and metabolic 
stability, which retain the activity profile of the parent nitro compound. These findings offer major 
assistance in the development of a preclinical candidate suitable for evaluation of the therapeutic 
potential of CB1 PAMs in a range of unmet medical needs. We hypothesise that the CF3 group might 
be a bioisosteric replacement for a nitro group also in other classes of bioactive compounds, especially 
when the nitro group is not involved in highly stabilizing hydrogen-bonds with the receptor, as the CF3 
group is known to be a weak hydrogen-bond acceptor. 
EXPERIMENTAL SECTION
General Methods: All reactions were carried out under a nitrogen atmosphere, with dry solvents 
under anhydrous conditions, unless otherwise mentioned. Solvents and reagents: Anhydrous 
tetrahydrofuran (THF), diethyl ether (Et2O), methylene chloride (CH2Cl2), and toluene were purchased 
from commercial suppliers. Reagents were purchased at the highest commercial quality, used without 
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further purification and handled in accordance with COSHH regulations. Chromatography: Flash 
chromatography (FC) was carried out on Silica gel (Merck Silica gel Si 60, 40-63 µm). Thin-layer 
chromatography (TLC) was carried out on glass-based 0.25 mm Merck silica gel plates (60F-254) which 
were developed with UV irradiation (254 nm and 365 nm), an aqueous solution of KMnO4 and an 
ethanolic solution of ammonium molybdate, and heat as developing agents. 1H NMR spectra: These 
were recorded at 400 MHz on a Bruker ADVANCEIII 400 instrument. Chemical shifts (δH) are given in 
parts per million (ppm) as referenced to the appropriate residual solvent peak. 13C NMR spectra: These 
were recorded at 100.6 MHz on a Bruker ADVANCE III 400 instrument. 19F NMR spectra: These were 
recorded at 376 MHz on a Bruker ADVANCE III 400 instrument without 1H decoupling. Chemical shifts 
(δC) are given in parts per million (ppm) as referenced to CFCl3 as 0 ppm. All NMR spectra were 
recorded at 298 K unless otherwise stated. Chemical shifts (δC) are given in parts per million (ppm) as 
referenced to CHCl3. The following abbreviations were used to explain the multiplicities: s = singlet, d 
= doublet, t = triplet, q = quartet, quint = quintet, m = multiplet, br = broad. Purity analysis: purities 
of all final compounds were determined by reverse phase HPLC-MS using an Agilent 1200 series 
chromatograph system coupled with an Agilent G6120 signal quadrupole detector equipped with an 
electrospray ionisation source and detection in positive mode. HPLC conditions for purity analysis: 
Phenomenex Luna C18(2) 100Å column, 4.6 × 250 mm, 5 μm; mobile phase: 75% MeOH / 25% H2O with 0.1% 
formic acid; flow rate: 1mL/min. All tested compounds were found to be at least 96% purity. Chiral separation: 
semi-preparative enantiomeric separations were carried out using an Agilent Technologies 1200 
Series HPLC system equipped with a DAD and a normal phase ChiralPak® IA (10.0 × 250 mm, 5 µm) 
chiral column from Daicel Chemical Industries Ltd. Optical rotations: These were measured on an AA-
65 Angular Scale automatic polarimeter from Optical Activity Limited with a 1 dm cell at the sodium D 
line. 
The following procedures for the preparation of CF3-PAMs 1, 41 and 52-56 are representative 
examples. 
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2-Phenyl-3-(3,3,3-trifluoro-1-(thiophen-2-yl)propyl)-1H-indole-6-carbonitrile (1)
To a solution of compound 82l (147 mg, 0.335 mmol) in THF (5 mL) was added 6 M HCl. (0.5 mL). The 
mixture was stirred at 60 °C for 16 h prior to quenching with a saturated solution of NaHCO3 (10 mL) 
and diluting with CH2Cl2 (10 mL). The layers were separated and the aqueous layer was extracted with 
CH2Cl2 (4 × 5 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo. 
The residue was passed through a short plug of silica gel (CH2Cl2) and concentrated in vacuo prior to 
use.
To a solution of the crude product in CH2Cl2 (5 mL) was added Et3SiH (233 mg, 320 µL, 2.0 mmol) and 
trifluoroacetic acid (193 mg, 130 µL, 1.689 mmol) at 0 °C. The resulting red solution was stirred at 23 
°C for 16 h before it was quenched with a saturated solution of NaHCO3 (10 mL) and diluted with CH2Cl2 
(10 mL). The layers were separated and the aqueous layer was extracted with CH2Cl2 (4 × 5 mL). The 
combined organic layers were dried over Na2SO4 and concentrated in vacuo. The residue was purified 
by flash column chromatography (silica gel, hexanes:EtOAc 10:1) to give compound 1 (102 mg, 77% 
for 2 steps) as pale yellow solid. 1H NMR (400 MHz, CDCl3) δ = 8.58 (s, 1H), 7.77 (dd, J = 1.3, 0.6 Hz, 
1H), 7.61 – 7.46 (m, 6H), 7.34 (dd, J = 8.3, 1.4 Hz, 1H), 7.22 (dd, J = 5.1, 0.8 Hz, 1H), 6.98 (dd, J = 5.1, 
3.6 Hz, 1H), 6.93 (dt, J = 3.6, 1.2 Hz, 1H), 4.96 (dd, J = 9.5, 4.8 Hz, 1H), 3.35 – 2.93 (m, 2H); 13C NMR 
(101 MHz, CDCl3) δ = 146.9, 140.2, 134.9, 131.2, 129.8, 129.3, 129.1, 128.8, 127.0, 126.0 (q, J = 277.9 
Hz), 124.5, 124.2, 123.0, 120.7, 120.5, 116.0, 113.6, 104.6, 39.2 (q, J = 37.5 Hz), 31.8 (q, J = 3.1 Hz); 19F 
NMR (376 MHz, CDCl3) δ = -64.34 (t, J = 10.2 Hz, 3F). m/z (ESI) 397.1 [M+H+].
6-Methyl-2-phenyl-3-(3,3,3-trifluoro-1-(thiophen-2-yl)propyl)-1H-indole (41)
Using the method analogous to prepare compound 1, with Et3SiH (176 mg, 242 µL, 1.51 mmol), 
compound 82a (108 mg, 0.25 mmol) and trifluoroacetic acid (144 mg, 97 µL, 1.26 mmol) were 
employed. Purification by flash column chromatography (silica gel, hexanes:EtOAc 10:1) to give 
compound 41 (64 mg, 66% for 2 steps) as a white solid. 1H NMR (400 MHz, CDCl3) δ = 7.95 (s, 1H), 7.62 
– 7.36 (m, 6H), 7.23 (s, 1H), 7.20 (dd, J = 4.2, 2.4 Hz, 1H), 7.04 – 6.91 (m, 3H), 4.97 (dd, J = 9.2, 4.8 Hz, 
1H), 3.30 – 3.16 (m, 1H), 3.16 – 3.00 (m, 1H), 2.53 (s, 3H); 13C NMR (101 MHz, CDCl3) δ = 148.0, 136.7, 
135.4, 132.6, 132.3, 128.9 128.7, 128.3, 126.8, 126.3 (q, J = 278.1 Hz), 124.5, 124.2, 124.1, 121.7, 119.9, 
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112.8, 111.3, 39.6 (q, J = 27.1 Hz), 32.1 (q, J = 3.2 Hz), 21.7; 19F NMR (376 MHz, CDCl3) δ = -64.42 (t, J = 
10.7 Hz, 3F). m/z (ESI) 386.1 [M+H+].
(2-Phenyl-3-(3,3,3-trifluoro-1-(thiophen-2-yl)propyl)-1H-indol-6-yl)methanol (52)
To a solution of compound 50 (15 mg, 0.035 mmol) in THF (2 mL) was added a solution of Super-
Hydride® (105 µL, 0.105 mmol, 1.0 M in THF) at 0 °C. The resulting mixture was stirred at 0 °C and 
allowed to warm to 23 °C for 16 h before it was quenched with a saturated solution of NH4Cl (10 mL) 
and diluted with CH2Cl2 (10 mL). The layers were separated and the aqueous layer was extracted with 
CH2Cl (4 x 5 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo. The 
residue was purified by flash column chromatography (silica gel, hexanes:EtOAc 5:1  1:1) to give 
compound 52 (13 mg, 94%) as a colourless oil. 1H NMR (400 MHz, CDCl3) δ = 8.13 (s, 1H), 7.69 – 7.35 
(m, 7H), 7.19 (dd, J = 4.7, 1.5 Hz, 1H), 7.12 (d, J = 8.1 Hz, 1H), 7.02 – 6.83 (m, 2H), 4.95 (dd, J = 9.3, 4.8 
Hz, 1H), 4.81 (s, 2H); 19F NMR (376 MHz, CDCl3) δ = -64.54 (t, J = 10.6 Hz, 3F). m/z (ESI) 424.1 [M+Na+].
N-(2-Phenyl-3-(3,3,3-trifluoro-1-(thiophen-2-yl)propyl)-1H-indol-6-yl)acetamide (53)
To a solution of compound 87 (15 mg, 0.027 mmol)in acetonitrile (2 mL) in a PTFE container was added 
an aqueous solution of HF (1 mL, 48 % wt) at 0 °C. The resulting solution was allowed to warm to 23 
°C and stirred for 16 h before it was quenched with a saturated solution of NaHCO3 (20 mL). The 
mixture was stirred at 23 °C for 10 min before EtOAc (20 mL) was added. The layers were separated 
and the organic layer was extracted with H2O (2 x 10 mL). The combined organic layers were dried 
over Na2SO4 and concentrated in vacuo. 
The residue was re-dissolved in MeOH (2 mL) and K2CO3 was added at 0 °C. The mixture was stirred at 
0 °C for 30 min prior to quenching with a saturated solution of NH4Cl and diluted with EtOAc (30 mL). 
The layers were separated and the organic layer was extracted with H2O (2 x 10 mL). The combined 
organic layers were dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash 
column chromatography (silica gel, hexanes:EtOAc 3:1) to give compound 53 (9 mg, 78% for 2 steps) 
as pale yellow solid. 1H NMR (400 MHz, CDCl3) δ = 8.56 (brs, 1H), 8.14 (d, J = 1.5 Hz, 1H), 7.57 – 7.45 
(m, 4H), 7.45 – 7.36 (m, 2H), 7.31 (s, 1H), 7.18 (dd, J = 5.0, 1.1 Hz, 1H), 6.97 – 6.89 (m, 2H), 6.79 (dd, J 
= 8.5, 1.8 Hz, 1H), 4.92 (dd, J = 8.9, 4.9 Hz, 1H), 3.22 – 2.93 (m, 2H), 2.17 (s, 3H); 13C NMR (101 MHz, 
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CDCl3) δ = 168.3, 148.2, 142.3, 137.8, 134.2, 132.9, 129.0, 128.6, 128.2, 126.9, 126.4 (q, J = 278.5 Hz), 
124.3, 121.1, 120.4, 113.1, 110.9, 97.0, 39.1 (q, J = 26.8 Hz), 32.2 (q, J = 2.8 Hz), 24.9; 19F NMR (376 
MHz, CDCl3) δ = -64.42 (t, J = 10.4 Hz, 3F). m/z (ESI) 429.1 [M+H+].
1-(2-Phenyl-3-(3,3,3-trifluoro-1-(thiophen-2-yl)propyl)-1H-indol-6-yl)ethan-1-one (54)
Using the method analogous to prepare compound 53, with compound 85 (22 mg, 0.04 mmol) was 
employed. Purification by flash column chromatography (silica gel, hexanes:EtOAc 3:1) to give 
compound 54 (12 mg, 72% for two steps) as a colourless oil. 1H NMR (400 MHz, CDCl3) δ = 8.59 (s, 1H), 
8.13 (s, 1H), 7.74 (dd, J = 8.4, 1.3 Hz, 1H), 7.59 – 7.42 (m, 6H), 7.20 (d, J = 4.8 Hz, 1H), 7.02 – 6.86 (m, 
2H), 4.96 (dd, J = 9.5, 4.6 Hz, 1H), 3.18 – 3.03 (m, 2H), 2.67 (s, 3H); 13C NMR (101 MHz, CDCl3) δ = 198.2, 
147.3, 140.1, 135.7, 131.7, 131.6, 130.4, 129.1, 128.7, 126.9, 126.2 (q, J = 276.2 Hz),  124.4, 124.2, 
120.4, 119.7, 113.3, 112.2, 39.4 (q, J = 27.1 Hz), 31.9 (q, J = 2.8 Hz), 26.8; 19F NMR (376 MHz, CDCl3) δ 
= -64.39 (t, J = 10.4 Hz, 3F). m/z (ESI) 414.1 [M+H+].
2-Phenyl-3-(3,3,3-trifluoro-1-(thiophen-2-yl)propyl)-1H-indol-6-amine (55)
Using the method analogous to prepare compound 53, with compound 88 (30 mg, 0.058 mmol) was 
employed. Purification by flash column chromatography (silica gel, hexanes:EtOAc 1:1) gave 
compound 55 (18 mg, 80% for 2 steps) as pale yellow solid. 1H NMR (400 MHz, CDCl3) δ = 7.86 (brs, 
1H), 7.53 – 7.42 (m, 4H), 7.41 (dd, J = 5.2, 3.6 Hz, 1H), 7.31 (s, 1H), 7.20 – 7.13 (m, 1H), 6.94 (d, J = 3.6 
Hz, 2H), 6.72 (d, J = 1.8 Hz, 1H), 6.56 (dd, J = 8.4, 2.0 Hz, 1H), 4.91 (dd, J = 8.8, 5.1 Hz, 1H), 3.28 – 2.55 
(m+brs, 4H); 13C NMR (101 MHz, CDCl3) δ = 148.0, 142.2, 137.6, 134.0, 132.7, 128.9, 128.5, 128.0, 
126.7, 126.3 (q, J = 277.1 Hz), 124.1, 120.9, 120.2, 112.9, 110.7, 96.8, 39.6 (q, J = 26.8 Hz), 32.0 (q, J = 
3.2 Hz); 19F NMR (376 MHz, CDCl3) δ = -64.45 (t, J = 10.6 Hz, 3F). m/z (ESI) 387.1 [M+H+].
N-(2-Phenyl-3-(3,3,3-trifluoro-1-(thiophen-2-yl)propyl)-1H-indol-6-yl)methanesulfonamide (56)
Using the method analogous to prepare compound 53, with compound 89 (32 mg, 0.054 mmol) was 
employed. Purification by flash column chromatography (silica gel, hexanes:EtOAc 1:1) gave 
compound 56 (20 mg, 81% for 2 steps) as pale yellow solid. 1H NMR (400 MHz, CDCl3) δ = 8.29 (brs, 
1H), 7.64 – 7.40 (m, 7H), 7.19 (dd, J = 5.0, 1.2 Hz, 1H), 7.02 – 6.91 (m, 2H), 6.89 (dd, J = 8.5, 2.0 Hz, 1H), 
6.67 (brs, 1H), 4.94 (dd, J = 9.1, 4.9 Hz, 1H), 3.22 – 3.01 (m, 2H), 3.00 (s, 3H); 13C NMR (101 MHz, CDCl3) 
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δ = 147.5, 137.1, 136.5, 132.0, 131.1, 129.0, 128.7, 126.8, 126.3 (q, J = 276.8 Hz), 125.0, 124.3, 124.1, 
120.9, 115.3, 112.8, 105.7, 39.4 (q, J = 27.2 Hz), 39.0, 31.9 (q, J = 3.1 Hz); 19F NMR (376 MHz, CDCl3) δ 
= -64.38 (t, J = 10.4 Hz, 3F). m/z (ESI) 464.1 [M+H+].
3-Ethynyl-1-(methoxymethyl)-6-methyl-2-phenyl-1H-indole (79a)
To a solution of 1-(methoxymethyl)-6-methyl-2-phenyl-1H-indole (575 mg, 2.29 mmol) in CH2Cl2 (10 
mL) was added N-iodosuccinimide (525 mg, 2.33 mmol) at 0 °C. The reaction mixture was stirred for 3 
h before it was quenched with a saturated solution of Na2SO3 (5 mL) and diluted with H2O (10 mL). 
The layers were separated and the aqueous layer was extracted with CH2Cl2 (3 × 10 mL). The combined 
organic layers were dried over Na2SO4 and concentrated in vacuo to give the corresponding 3-iodo-
indole, which was used without further purification.
To a solution of the crude 3-iodo-indole in DMF (5 mL) was added trimethylsilylacetylene (337 mg, 475 
µL, 3.43 mmol), PdCl2(PPh3)2 (80 mg, 0.114 mmol), CuI (26 mg, 0.137 mmol) and Et3N (695 mg, 957 µL, 
6.87 mmol) at 23 °C. The reaction mixture was stirred for 6 h at 23 °C before it was quenched with a 
saturated solution of NH4Cl (10 mL) and diluted with EtOAc (50 mL). The layers were separated, and 
the organic layer was extracted with H2O (3 x 10 mL). The combined organic layers were dried over 
Na2SO4 and concentrated in vacuo. The residue was passed through a short plug of silica gel (CH2Cl2) 
and concentrated in vacuo prior to use.
To a solution of the crude product was added a solution of tetra-n-butylammonium fluoride (2.8 mL, 
2.8 mmol, 1.0 M in THF) at 0 °C. The reaction mixture was stirred for 2 h at 23 °C before it was it was 
quenched with a saturated solution of NH4Cl (10 mL) and diluted with EtOAc (50 mL). The layers were 
separated, and the organic layer was extracted with H2O (3 x 10 mL). The combined organic layers 
were dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography (silica gel, hexanes:EtOAc 5:1) to give compound 79a (566 mg, 90% for 3 steps). 1H 
NMR (400 MHz, CDCl3) δ = 7.76 – 7.66 (m, 1H), 7.59 – 7.44 (m, 5H), 7.40 – 7.33 (m, 1H), 7.15 (d, J = 8.0 
Hz, 1H), 5.39 (s, 2H), 3.28 (s, 3H), 3.18 (s, 1H), 2.56 (s, 3H); 13C NMR (101 MHz, CDCl3) δ = 144.4, 137.1, 
133.6, 131.2, 130.5, 130.3, 128.8, 128.5, 127.2, 123.4, 119.7, 110.5, 79.7, 78.00, 74.9, 56.0, 22.0. m/z 
(ESI) 276.1 [M+H+].
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3-Ethynyl-1-(methoxymethyl)-2-phenyl-1H-indole-6-carbonitrile (79g)
Using the method analogous to prepare compound 79a, with compound 94d (700 mg, 2.67 mmol), N-
iodosuccinimide (616 mg, 2.74 mmol), trimethylsilylacetylene (394 mg, 555 µL, 4.01 mmol), 
PdCl2(PPh3)2 (94 mg, 0.134 mmol), CuI (25 mg, 0.131 mmol), Et3N (813 mg, 1.12 mL, 8.03 mmol) and 
tetra-n-butylammonium fluoride (3.40 mL, 3.40 mmol, 1.0 M in THF) were used. Purification by flash 
column chromatography (silica gel, hexanes:EtOAc 5:1) gave compound 79g (596 mg, 78% for 3 steps) 
as a colourless oil. 1H NMR (400 MHz, CDCl3) δ = 7.88 (d, J = 0.5 Hz, 1H), 7.85 (dd, J = 8.2, 0.5 Hz, 1H), 
7.72 (d, J = 1.8 Hz, 1H), 7.70 (d, J = 1.4 Hz, 1H), 7.61 – 7.49 (m, 4H), 5.41 (s, 2H), 3.30 (s, 3H), 3.19 (s, 
1H); 13C NMR (101 MHz, CDCl3) δ = 147.8, 135.5, 132.5, 130.2, 129.7, 129.1, 129.0, 128.8, 124.6, 120.9, 
120.2, 115.5, 106.1, 80.9, 76.2, 75.3, 56.3. m/z (ESI) 309.1 [M+Na+].
1-(Methoxymethyl)-6-methyl-2-phenyl-3-(3,3,3-trifluoroprop-1-yn-1-yl)-1H-indole (80a)
Using a method described by Blanchard,27 to a solution of N,N,N´,N´-tetramethylethylenediamine (324 
mg, 418 µL, 2.79 mmol) in DMF (5 mL) was added CuI (531 mg, 2.79 mmol) and K2CO3 (771 mg, 5.58 
mmol) at 23 °C. The resulting blue mixture was stirred vigorously at 23 °C under air (1 atm) for 20 min 
before trimethyl(trifluoromethyl)silane (529 mg, 550 µL, 3.72 mmol) was added and the resulting 
mixture was stirred for further 15 min under air. After which time, the deep green mixture was cooled 
to 0 °C prior to adding a mixture of compound 79a (512 mg, 1.86 mmol) and 
trimethyl(trifluoromethyl)silane (529 mg, 550 µL, 3.72 mmol) in DMF (2 mL). The reaction mixture was 
stirred at 0 °C for 30 min and allowed to warm to 23 °C for 6 h before it was quenched with a saturated 
solution of NH4Cl (10 mL) and diluted with EtOAc (50 mL). The layers were separated, and the organic 
layer was extracted with H2O (3 x 10 mL). The combined organic layers were dried over Na2SO4 and 
concentrated in vacuo. The residue was purified by flash column chromatography (silica gel, 
hexanes:EtOAc 4:1) to give compound 80a (556 mg, 87%) as a pale yellow oil. 1H NMR (400 MHz, CDCl3) 
δ = 7.75 – 7.64 (m, 3H), 7.64 – 7.47 (m, 3H), 7.39 (s, 1H), 7.19 (d, J = 8.0 Hz, 1H), 5.40 (s, 2H), 3.32 (s, 
3H), 2.58 (s, 3H); 13C NMR (101 MHz, CDCl3) δ = 147.0 (q, J = 1.7 Hz), 137.1, 134.3, 130.1, 129.50, 
129.47, 128.8, 126.5, 124.1, 119.4, 115.5 (q, J = 256.2 Hz), 110.9, 93.6 (q, J = 2.5 Hz), 83.3 (q, J = 6.2 
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Hz), 78.7 (q, J = 52.2 Hz), 75.0, 56.1, 22.0; 19F NMR (376 MHz, CDCl3) δ = -48.59 (s, 3F). m/z (ESI) 344.1 
[M+H+].
1-(Methoxymethyl)-2-phenyl-3-(3,3,3-trifluoroprop-1-yn-1-yl)-1H-indole-6-carbonitrile (80g)
Using the method analogous to prepare compound 80a, with compound 79g (300 mg, 1.05 mmol), 
N,N,N´,N´-tetramethylethylenediamine (185 mg, 255 µL, 1.57 mmol), CuI (300 mg, 1.58 mmol), K2CO3 
(435 mg, 3.15 mmol) and trimethyl(trifluoromethyl)silane (596 mg, 620 µL, 4.19 mmol) were used. 
Purification by flash column chromatography (silica gel, hexanes:EtOAc 6:1) gave compound 80g (352 
mg, 95%) as a pale yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.92 (s, 1H), 7.83 (d, J = 8.2 Hz, 1H), 7.72 – 
7.65 (m, 2H), 7.64 – 7.59 (m, 3H), 7.56 (dd, J = 8.2, 1.2 Hz, 1H), 5.44 (s, 2H), 3.33 (s, 3H); 13C NMR (101 
MHz, CDCl3) δ = 150.5 (q, J = 1.7 Hz), 135.6, 131.8, 130.4, 130.0, 129.0, 128.2, 125.3, 120.7, 119.7, 
115.9, 115.1 (q, J = 256.4 Hz), 106.9, 94.5 (q, J = 2.2 Hz), 81.1 (q, J = 6.2 Hz), 79.5 (q, J = 52.4 Hz), 75.4, 
56.4. 19F NMR (376 MHz, CDCl3) δ = -49.13 (s, 3F). m/z (ESI) 355.1 [M+H+].
(E)-1-(Methoxymethyl)-6-methyl-2-phenyl-3-(3,3,3-trifluoro-1-iodoprop-1-en-1-yl)-1H-indole (81a)
Using a modified method described by Zhong,28 to a solution of compound 80a (420 mg, 1.22 mmol) 
in CH2Cl2 (4 mL) was added LiI (180 mg, 1.35 mmol) and HOAc (1 mL) at 0 °C. The resulting mixture was 
stirred at 23 °C for 16 h before it was quenched with a saturated solution of NaHCO3 (10 mL) and 
diluted with CH2Cl2 (10 mL). The layers were separated, and the aqueous layer was extracted with 
CH2Cl2 (2 × 10 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo. 
The residue was purified by flash column chromatography (silica gel, hexanes:EtOAc 10:1) to give 
compound 81a (558 mg, 97%) as a pale yellow solid. 1H NMR (400 MHz, CDCl3) δ = 7.65 – 7.48 (m, 6H), 
7.38 (s, 1H), 7.24 – 7.14 (m, 1H), 6.71 (q, J = 7.1 Hz, 1H), 5.38 (s, 2H), 3.25 (s, 3H), 2.58 (s, 3H); 13C NMR 
(101 MHz, CDCl3) δ = 137.5, 137.0, 133.6, 132.0 (q, J = 33.9 Hz), 130.4, 130.2, 129.0, 128.6, 124.0, 
123.3, 121.3 (q, J = 274.4 Hz), 119.4, 115.8, 110.6, 104.4 (q, J = 6.2 Hz), 74.8, 55.9, 22.0; 19F NMR (376 
MHz, CDCl3) δ = -60.80 (d, J = 7.1 Hz, 3F). m/z (ESI) 472.0 [M+H+].
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(E)-1-(methoxymethyl)-2-phenyl-3-(3,3,3-trifluoro-1-iodoprop-1-en-1-yl)-1H-indole-6-carbonitrile 
(81g)
Using the method analogous to prepare compound 81a, with compound 80g (330 mg, 0.931mmol) 
and LiI (150 mg, 1.12 mmol). The residue was passed through a short plug of silica gel (CH2Cl2) and 
concentrated in vacuo to give compound 81g, which was used without further purification.
(E)-1-(Methoxymethyl)-6-methyl-2-phenyl-3-(3,3,3-trifluoro-1-(thiophen-2-yl)prop-1-en-1-yl)-1H-
indole (82a)
To a solution of compound 81a (146 mg, 0.31 mmol) in DMF (5 mL) was added tri-n-butyl(thiophen-2-
yl)stannane (175 mg, 0.47 mmol), P(o-Tol)3 (14 mg, 0.046 mmol), PdCl2(MeCN)2 (7.8 mg, 0.03 mmol) 
and CuI (9 mg, 0.046 mmol) at 23 °C. The resulting mixture was stirred at 23 °C for 20 min before it 
was heated to 55 °C for 3 h. After which time, the reaction mixture was quenched with a saturated 
solution of NH4Cl (10 mL) and diluted with Et2O (50 mL). The layers were separated, and the organic 
layer was extracted with H2O (3 x 10 mL). The combined organic layers were dried over Na2SO4 and 
concentrated in vacuo. The residue was purified by flash column chromatography (silica gel, 
hexanes:EtOAc 10:1) to give compound 82a (120 mg, 90%) as a colourless oil. 1H NMR (400 MHz, CDCl3) 
δ = 7.50 – 7.31 (m, 7H), 7.27 (d, J = 5.0 Hz, 1H), 7.06 (d, J = 8.1 Hz, 1H), 6.98 (d, J = 3.4 Hz, 1H), 6.91 
(dd, J = 4.9, 3.8 Hz, 1H), 6.31 (q, J = 8.0 Hz, 1H), 5.46 (s, 2H), 3.24 (s, 3H), 2.57 (s, 3H); 13C NMR (101 
MHz, CDCl3) δ = 144.3, 138.4 (q, J = 5.5 Hz), 137.3, 132.9, 130.8, 130.3, 128.4, 128.3, 128.1, 127.7, 
127.4, 126.2, 123.1 (q, J = 270.6 Hz), 123.0, 119.4, 115.1 (q, J = 33.4 Hz),111.1, 110.5, 74.8, 55.6, 22.0; 
19F NMR (376 MHz, CDCl3) δ = -58.23 (d, J = 8.0 Hz, 3F). m/z (ESI) 428.1 [M+H+].
(E)-1-(methoxymethyl)-2-phenyl-3-(3,3,3-trifluoro-1-(thiophen-2-yl)prop-1-en-1-yl)-1H-indole-6-
carbonitrile (82l)
Using the method analogous to prepare compound 82a, with compound 81g (449 mg, 0.931 mmol), 
tri-n-butyl(thiophen-2-yl)stannane (522 mg, 1.40 mmol), P(o-Tol)3 (43 mg, 0.141 mmol), PdCl2(MeCN)2 
(24 mg, 0.093 mmol) and CuI (18 mg, 0.095 mmol) were used. Purification by flash column 
chromatography (silica gel, hexanes:EtOAc 5:1) gave compound 82l (334 mg, 82%) as a pale yellow oil. 
1H NMR (400 MHz, CDCl3) δ = 7.93 (s, 1H), 7.48 (d, J = 8.3 Hz, 1H), 7.45 – 7.32 (m, 6H), 7.31 – 7.23 (m, 
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1H), 6.93 – 6.83 (m, 2H), 6.30 (q, J = 8.2 Hz, 1H), 5.47 (s, 2H), 3.26 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
= 143.5, 142.6, 137.1 (q, J = 6.0 Hz), 135. 6, 131.1, 130.1, 129.5, 129.3, 128.5, 128.2, 127.89, 127.86, 
124.2, 123.3 (q, J = 268.2 Hz), 121.5, 120.3, 115.9 (q, J = 34.2 Hz), 115.7, 111.4, 105.3, 75.1, 56.0; 19F 
NMR (376 MHz, CDCl3) δ = -58.18 (d, J = 8.2 Hz, 3F). m/z (ESI) 439.1 [M+H+].
Methyl 2-phenyl-3-(3,3,3-trifluoro-1-(thiophen-2-yl)propyl)-1-((2-(trimethylsilyl)-ethoxy)methyl)-
1H-indole-6-carboxylate (83)
To a solution of compound 50 (540 mg, 1.257 mmol) in THF (3 mL) was added NaH (75 mg, 1.886 
mmol, 60 % in mineral oil) at 0 °C.  After stirring at 0 °C for 30 min, 2-(trimethylsilyl)ethoxymethyl 
chloride (SEM-Cl, 282 mg, 300 µL, 1.51 mmol, 90% technical grade) was added. The resulting reaction 
mixture was stirred at 0 °C and allowed to warm to 23 °C for 3 h before it was quenched with a 
saturated solution of NH4Cl (5 mL) and diluted with EtOAc (50 mL). The layers were separated and the 
organic layer was extracted with H2O (4 x 10 mL). The combined organic layers were dried over Na2SO4 
and concentrated in vacuo. The residue was purified by flash column chromatography (silica gel, 
hexanes:EtOAc 5:1) to give compound 83 (680 mg, 97%) as a colourless oil. 1H NMR (400 MHz, CDCl3) 
δ = 8.33 (s, 1H), 7.85 (dd, J = 8.4, 1.3 Hz, 1H), 7.59 – 7.39 (m, 6H), 7.16 (d, J = 5.0 Hz, 1H), 6.93 (dd, J = 
5.1, 3.6 Hz, 1H), 6.86 (d, J = 3.5 Hz, 1H), 5.41 (s, 2H), 4.65 (dd, J = 9.9, 4.3 Hz, 1H), 3.97 (s, 3H), 3.34 
(ABq, J = 7.6 Hz, 2H), 3.26 – 3.08 (m, 1H), 3.08 – 2.92 (m, 1H), 0.80 (ABq, J = 7.6 Hz, 2H), -0.07 (s, 9H); 
13C NMR (101 MHz, CDCl3) δ = 167.9, 147.3, 142.0, 136.7, 130.8, 130.2, 129.6, 129.3, 128.6, 126.7, 
126.1 (q, J = 277.1 Hz), 124.2, 124.0, 123.8, 121.5, 119.4, 114.7, 113.1, 94.3, 72.9, 65.8, 52.0, 39.0 (q, 
J = 27.5 Hz), 32.1 (q, J = 2.6 Hz), 17.8, -1.5; 19F NMR (376 MHz, CDCl3) δ = -64.20 (t, J = 10.4 Hz, 3F). m/z 
(ESI) 560.2 [M+H+].
N-Methoxy-N-methyl-2-phenyl-3-(3,3,3-trifluoro-1-(thiophen-2-yl)propyl)-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-indole-6-carboxamide (84)
Using a modified method described by Williams,33 to a solution of compound 83 (408 mg, 0.729 mmol) 
and N,O-dimethylhydroxylamine hydrochloride (108 mg, 1.11 mmol) in THF (3 mL) was added a 
solution of isopropylmagnesium chloride (1.10 mL, 2.19 mmol, 2.0 M in THF)  at 0 °C. After stirring at 
0 °C for 30 min, the solution was allowed to warm to 23 °C and stirred for further 3 h before it was 
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quenched with a saturated solution of NH4Cl (5 mL) and diluted with EtOAc (50 mL). The layers were 
separated and the organic layer was extracted with H2O (4 x 10 mL). The combined organic layers were 
dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography (silica gel, hexanes:EtOAc 3:1) to give compound 84 (326 mg, 76%) as a colourless oil. 
1H NMR (400 MHz, CDCl3) δ = 8.00 (s, 1H), 7.61 – 7.39 (m, 7H), 7.16 (dd, J = 5.1, 0.9 Hz, 1H), 6.92 (dd, 
J = 5.1, 3.6 Hz, 1H), 6.87 (dt, J = 3.5, 1.2 Hz, 1H), 5.38 (ABq, J = 12.7 Hz, 2H), 4.64 (dd, J = 9.7, 4.3 Hz, 
1H), 3.65 (s, 3H), 3.42 (s, 3H), 3.33 (ddd, J = 9.5, 6.2, 1.9 Hz, 2H), 3.25 – 3.09 (m, 1H), 3.12 – 2.89 (m, 
1H), 0.80 (ddd, J = 9.5, 6.2, 1.9 Hz, 2H), -0.07 (s, 9H); 13C NMR (101 MHz, CDCl3) δ = 170.7, 147.4, 140.9, 
136.4, 130.9, 130.4, 129.2, 128.6, 127.9, 127.8, 126.7, 126.2 (q, J = 278.5 Hz), 124.2, 123.8, 120.7, 
119.3, 114.5, 111.8, 73.0, 65.7, 61.0, 39.0 (q, J = 27.2 Hz), 34.4, 32.1 (q, J = 2.8 Hz), 17.8, -1.5; 19F NMR 
(376 MHz, CDCl3) δ = -64.19 (t, J = 10.3 Hz, 3F). m/z (ESI) 589.2 [M+H+].
1-(2-Phenyl-3-(3,3,3-trifluoro-1-(thiophen-2-yl)propyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
indol-6-yl)ethan-1-one (85)
To a solution of compound 84 (408 mg, 0.54 mmol) in THF (3 mL) was added a solution of 
methyllithium (860 µL, 0.860 mmol, 1.6 M in Et2O) at -78 °C. After stirring at -78 °C for 30 min, the 
solution was allowed to warm to 0 °C and stirred for further 3 h before it was quenched with a 
saturated solution of NH4Cl (5 mL) and 0.1 M HCl solution (5 mL). The mixture was stirred at 23 °C for 
10 min before EtOAc (50 mL) was added. The layers were separated and the organic layer was 
extracted with H2O (4 x 10 mL). The combined organic layers were dried over Na2SO4 and concentrated 
in vacuo. The residue was purified by flash column chromatography (silica gel, hexanes:EtOAc 5:1) to 
give compound 85 (252 mg, 86%) as a colourless oil. 1H NMR (400 MHz, CDCl3) δ = 8.26 (s, 1H), 7.80 
(dd, J = 8.4, 1.4 Hz, 1H), 7.64 – 7.41 (m, 6H), 7.17 (dd, J = 5.1, 1.0 Hz, 1H), 6.94 (dd, J = 5.1, 3.6 Hz, 1H), 
6.90 – 6.84 (m, 1H), 5.44 (s, 2H), 4.66 (dd, J = 10.0, 4.2 Hz, 1H), 3.41 – 3.30 (m, 2H), 3.25 – 3.10 (m, 
1H), 3.09 – 2.95 (m, 1H), 2.71 (s, 3H), 0.85 – 0.74 (m, 2H), -0.06 (s, 9H); 13C NMR (101 MHz, CDCl3) δ = 
198.0, 147.3, 142.5, 136.8, 131.7, 130.8, 130.1, 129.8, 129.4, 128.6, 126.8, 126.1 (q, J = 277.4 Hz), 
124.3, 123.8, 120.8, 119.5, 114.8, 111.8, 73.0, 65.9, 38.9 (q, J = 27.6 Hz), 32.1 (q, J = 3.3 Hz), 26.82, 
17.78, -1.49; 19F NMR (376 MHz, CDCl3) δ = -64.14 (t, J = 10.3 Hz, 3F). m/z (ESI) 544.2 [M+H+].
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(E)-/(Z)-1-(2-Phenyl-3-(3,3,3-trifluoro-1-(thiophen-2-yl)propyl)-1-((2-(trimethyl-
silyl)ethoxy)methyl)-1H-indol-6-yl)ethan-1-one oxime (86)
To a solution of compound 85 (220 mg, 0.405 mmol) in MeOH (5 mL) was added hydroxylamine 
hydrochloride (34 mg, 0.489 mmol) and sodium acetate (50 mg, 0.61 mmol). The resulting mixture 
was heated to 70 °C for 4 h before it was cooled to 23 °C and quenched with a saturated solution of 
NH4Cl (10 mL) and then diluted with CH2Cl2 (10 mL). The layers were separated and the aqueous layer 
was extracted with CH2Cl2 (4 x 5 mL). The combined organic layers were dried over Na2SO4 and 
concentrated in vacuo to give oxime 86 as a mixture of (E)- and (Z)-isomers. Oxime 86 was used 
without further purification.
N-(2-Phenyl-3-(3,3,3-trifluoro-1-(thiophen-2-yl)propyl)-1-((2-(trimethylsilyl)-ethoxy)methyl)-1H-
indol-6-yl)acetamide (87)
Using a modified method described by Giacomelli,34 2,4,6-trichloro-[1,3,5]triazine (cyanuric chloride, 
32 mg, 0.445 mmol) was added DMF (1 mL) at 23 °C and stirred for 30 min before a solution of oxime 
86 (226 mg, 0.404 mmol) in DMF (1 mL) was added. The resulting mixture was stirred for 4 h at 23 °C 
prior to quenching with a saturated solution of NaHCO3 (10 mL) and diluted with EtOAc (50 mL). The 
layers were separated and the organic layer was extracted with H2O (4 x 10 mL). The combined organic 
layers were dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography (silica gel, hexanes:EtOAc 1:1) to give compound 87 (208 mg, 92% for 2 steps) as a 
pale yellow oil. 1H NMR (400 MHz, CDCl3) δ = 8.01 (d, J = 1.0 Hz, 1H), 7.59 (s, 1H, NH), 7.55 – 7.42 (m, 
5H), 7.40 (d, J = 8.5 Hz, 1H), 7.14 (d, J = 5.0 Hz, 1H), 7.05 (dd, J = 8.5, 1.5 Hz, 1H), 6.96 – 6.88 (m, 1H), 
6.86 (d, J = 3.4 Hz, 1H), 5.31 (s, 2H), 4.62 (dd, J = 9.5, 4.3 Hz, 1H), 3.32 (ddd, J = 9.7, 5.2, 3.0 Hz, 2H), 
3.21 – 3.07 (m, 1H), 3.07 – 2.91 (m, 1H), 2.19 (s, 3H), 0.82 – 0.73 (m, 2H), -0.07 (s, 9H); 13C NMR (101 
MHz, CDCl3) δ = 168.4, 147.8, 138.9, 137.5, 133.1, 131.0, 130.7, 128.9, 128.5, 126.7, 126.2 (q, J = 279.0 
Hz), 124.1, 123.7, 123.0, 120.0, 114.3, 114.0, 103.1, 72.8, 65.6, 39.0 (q, J = 27.1 Hz), 32.1 (q, J = 2.7 Hz), 
24.6, 17.8, -1.5; 19F NMR (376 MHz, CDCl3) δ = -64.19 (t, J = 10.3 Hz, 3F). m/z (ESI) 559.2 [M+H+].
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2-Phenyl-3-(3,3,3-trifluoro-1-(thiophen-2-yl)propyl)-1-((2-(trimethylsilyl)ethoxy)-methyl)-1H-indol-
6-amine (88)
To a solution of compound 87 (106 mg, 0.19 mmol) in EtOH (2 mL) in a sealable tube was added 
hydrazine hydrate (50 µL, 1.03 mmol). The tub was sealed and heated to 100 °C for 16 h before the 
reaction mixture was quenched with 0.1 M HCl (1 mL) and diluted with EtOAc (50 mL). The layers were 
separated, and the organic layer was washed with a saturated solution of NaHCO3 (2 x 10 mL) and H2O 
(2 x 10 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give 
compound 32 as a pale yellow solid. Compound 88 was used without further purification.
N-(2-Phenyl-3-(3,3,3-trifluoro-1-(thiophen-2-yl)propyl)-1-((2-(trimethylsilyl)-ethoxy)methyl)-1H-
indol-6-yl)methanesulfonamide (89)
To a solution of compound 88 (37 mg, 0.072 mmol) in CH2Cl2 (2 mL) was added pyridine (10 µL, 0.124 
mmol) at 0 °C followed by methanesulfonyl chloride (6 µL, 0.078 mmol). The resulting mixture was 
stirred at 0 °C before it was quenched by a saturated solution of NaHCO3 (5 mL) and diluted with EtOAc 
(20 mL). The layers were separated and the organic layer was extracted with H2O (2 x 10 mL). The 
combined organic layers were dried over Na2SO4 and concentrated in vacuo to give compound 89 as 
a yellow oil. The residue was used without further purification.
CCI mouse model of neuropathic pain: Subjects consisted of male C57BL/6J mice (6-8 weeks old, body 
mass of 27–32 g) obtained from the Virginia Commonwealth University Transgenic Mouse Core 
(Richmond, Virginia). Mice were group-housed (four per cage) for at least one week before the 
beginning of experiments on a 12/12 light/dark cycle (lights on at 0600 h), with an ambient 
temperature of 20–22 °C and humidity of 55–60%. Standard rodent chow and water were available 
ad libitum. Animal experiments were conducted in accordance with the guidelines of the Institutional 
Animal Care and Use Committee of Virginia Commonwealth University and followed the NIH 
Guidelines for the Care and Use of Laboratory Animals.  (±)-1 was dissolved in ethanol (5% of total 
volume), alkamuls-620 (Sanofi-Aventis, Bridgewater, NJ) (5% of total volume), and saline (0.9 % NaCl) 
(90% of total volume) and administered intraperitoneally in a volume of 10 mL/kg.
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The CCI model of neuropathic pain was used to assess the anti-allodynic effects of (±)-1. Surgical 
procedure for chronic constriction of the sciatic nerve was performed as previously described,35 but 
modified for the mouse.36 In brief, the mice were anesthetized with isoflurane (induction 5% vol. 
followed by 2.0% in oxygen), and the right hind leg was shaved and cleaned with betadine and ethanol. 
Using aseptic procedures, the sciatic nerve was carefully isolated and loosely ligated using three 
segments of 5–0 chromic gut sutures (Ethicon, Somerville, NJ, USA). Sham surgery was identical to CCI 
surgery, but the nerve was neither ligated nor manipulated. The overlying muscle was sutured closed 
with (1) 4–0 sterile silk suture (Ethicon), and animals recovered from anaesthesia within approximately 
5 min. Mice were randomly assigned into the CCI or sham surgical groups. 
Behavioral assessment of mechanical allodynia
Following 15/20 minutes of habituation to the testing environment, von Frey filaments were used to 
determine baseline paw withdrawal responses, as previously described.37 Mice were unrestrained and 
were singly placed under an inverted wire mesh basket to allow for unrestricted air flow and the 
mechanical allodynia was assessed with von Frey filaments (North Coast Medical, Morgan Hill, CA) 
applied randomly to the left and right plantar surfaces of the hind paw. Lifting, licking or shaking the 
paw in response to three stimulations was coded as a positive response. Basal von Frey paw 
withdrawal responses were assessed prior to CCI or sham surgery (pre-sx) and again on post-surgery 
day 7 prior to drug administration (post-sx). Following the assessment of von Frey thresholds on day 
7, CCI and sham mice were assigned to different treatment groups and were given a singular i.p. 
injection of vehicle or (±)-1 (40 mg/kg).  Each mouse was tested for paw withdrawal thresholds 0.5 h, 
1 h, 2 h, 4 h, and 8 h after the injections.
Statistical analysis
For all in vivo data, statistical analyses were performed using the computer program GraphPad Prism 
version 6.0 (GraphPad Software, Inc., San Diego, CA).  Data were analyzed by two-way analysis of 
variance (ANOVA) with drug treatment as a between subject factor and time as a within subject factor. 
Page 31 of 37
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
A P value of <0.05 was considered statistically significant. Following significant ANOVAs, the Bonferroni 
post-hoc test was used to ascertain further differences for both ipsilateral and contralateral paws. All 
data are expressed as the mean ± SEM.
PathHunter® β-Arrestin assay. 
Beta-arrestin recruitment studies were conducted by Eurofins DiscoverX, using the PathHunter® β-
arrestin assay. Briefly, this assay monitors the activation of CB1 using enzyme fragment 
complementation, with β-galactosidase as the functional reporter.  When the CB1 receptor is activated 
and β-arrestin is recruited to the receptor, enzyme complementation occurs, restoring β-galactosidase 
activity, effecting substrate transformation.  Product formation is detected by chemiluminescence.  
PathHunter cell lines were expanded from freezer stocks according to standard procedures.  Cells were 
seeded in a total volume of 20 μL into white walled, 384-well microplates and incubated at 37 °C for 
the appropriate time prior to testing. Cells were pre-incubated with sample followed by agonist 
induction at the EC20 concentration of CP55,940 (2 nM). Intermediate dilution of sample stocks was 
performed to generate 5X sample in assay buffer.  5 μL of 5x sample was added to cells and incubated 
at 37 °C or room temperature for 30 min. Vehicle concentration was 1%.  5 μL of 6X EC20 agonist in 
assay buffer was added to the cells and incubated at 37 °C or room temperature for 90 or 180 min. 
Assay signal was generated through a single addition of 12.5 or 15 μL (50% v/v) of PathHunter 
Detection reagent cocktail, followed by a 1 h incubation at room temperature.  Microplates were read 
following signal generation with a PerkinElmer EnvisionTM instrument for chemiluminescent signal 
detection. Compound activity was analyzed using CBIS data analysis suite (ChemInnovation, CA).  
Percentage modulation was calculated using the following formula: % Modulation =100% x ((mean 
RLU of test sample - mean RLU of EC20 control) / (mean RLU of MAX control ligand - mean RLU of EC20 
control)).
Hit Hunter® cAMP assay
cAMP generation studies were conducted by Eurofins DiscoverX as described previously.7 Briefly, cells 
were pre-incubated with sample followed by agonist induction at the EC20 concentration (0.09 nM 
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CP55,940). Media was aspirated from cells and replaced with 10 μL 1:1 HBSS/10 mM Hepes : cAMP 
XS+ Ab reagent. Intermediate dilution of sample stocks was performed to generate 4X sample in assay 
buffer. 5 μL of 4X compound was added to the cells and incubated at room temperature or 37 °C for 
30 minutes. 5 μL of 4X EC20 agonist was added to the cells and incubated at room temperature or 37 
°C for 30 or 60 minutes. EC80 forskolin (20 μM) was included. After appropriate compound incubation, 
assay signal was generated through incubation with 20 μL cAMP XS+ ED/CL lysis cocktail for 1 h 
followed by incubation with 20 μL cAMP XS+ EA reagent for 3 h at room temperature. Microplates 
were read following signal generation with a PerkinElmer EnvisionTM instrument for 
chemiluminescent signal detection.  Compound activity was analyzed using CBIS data analysis suite 
(ChemInnovation, CA).  Percentage modulation is calculated using the following formula: % 
Modulation =100% x (1-(mean RLU of test sample - mean RLU of MAX control) / (mean RLU of EC20 
control - mean RLU of MAX control)).
 
Pharmacokinetics Assays. Routine in vitro stability studies were conducted by Cyprotex Ltd. 
(Macclesfield, U.K.)
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